New drug cocktail aims to beat back tough leukemia

NCT ID NCT06084819

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding venetoclax to a five-drug regimen (CACAG) works better than standard treatments for people whose acute myeloid leukemia has returned or not responded. About 200 adults aged 14 to 75 will be randomly assigned to one of the two approaches. The main goal is to see how many patients achieve remission after one treatment cycle.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax combined with azacytidine, cytarabine, aclacinomycin, chidamide, and granulocyte colony-stimulating factor
What this could lead to: If successful, this could offer a new treatment option for people with relapsed or hard-to-treat acute myeloid leukemia.
What could go wrong: This is a Phase 2 trial with 200 participants, so results are still early. The combination may cause serious side effects and may not work better than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.